BioVie Inc. (NASDAQ:BIVIW – Get Free Report) was the target of a large decrease in short interest in the month of September. As of September 30th, there was short interest totaling 20,933 shares, a decrease of 51.6% from the September 15th total of 43,287 shares. Based on an average trading volume of 15,170 shares, the short-interest ratio is currently 1.4 days.
BioVie Stock Performance
NASDAQ BIVIW traded up $0.01 on Wednesday, hitting $0.26. The stock had a trading volume of 6,184 shares, compared to its average volume of 55,578. The firm has a 50-day moving average of $0.30 and a 200-day moving average of $0.33. BioVie has a 52-week low of $0.13 and a 52-week high of $0.79.
BioVie Inc is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and liver-related diseases. The company’s research programs are intended to address conditions associated with neuroinflammation, insulin resistance, chronic liver disease and complications of cirrhosis.
BioVie’s lead neurodegenerative disease candidate is bezisterim, also known as NE3107, an orally administered investigational therapy designed to cross the blood-brain barrier and modulate inflammatory signaling.
Further Reading
- Five stocks we like better than BioVie
- High Voltage Returns: Navitas Rewires AI Data Centers
- Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built
- Albertsons Is Betting on a Turnaround—But Will It Pay Off?
- Venezuela’s Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.
